Court: United States District Court, Eastern District of Pennsylvania

Leadership Position: Interim Co-Lead Counsel

Result: $30 million settlement

WBE and its co-counsel filed this case on behalf of a class of end payors against Reckitt Benckiser for allegedly engaging in an anticompetitive scheme to exclude generic competition for its opiate treatment drug, Suboxone. Plaintiffs further alleged that Reckitt filed sham citizen petitions with the Food and Drug Administration (“FDA”) to sabotage the FDA’s Abbreviated New Drug Application process for approving generic alternatives to further delay generic entry and buy time to convert consumers from the tablet to the film.

In December 2023, the Court granted final approval of a $30 million settlement.